Cargando…

Adjuvant treatment for triple negative breast cancer with residual tumor after neo-adjuvant chemotherapy. A single institutional retrospective analysis

PURPOSE: Incomplete response to neoadjuvant chemotherapy (NACT) in triple negative breast cancer (TNBC) patients is correlated to high risk of relapse. This study aimed to evaluate the role of adjuvant chemotherapy in TNBC with residual tumor after NACT. METHODS: We retrospectively reviewed the outc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bianco, Nadia, Palazzo, Antonella, Pagan, Eleonora, Bagnardi, Vincenzo, Milano, Monica, De Maio, Ana Paula, Colleoni, Marco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8377481/ https://www.ncbi.nlm.nih.gov/pubmed/34407499 http://dx.doi.org/10.1016/j.breast.2021.08.004

Ejemplares similares

Prognosis of selected triple negative apocrine breast cancer patients who did not receive adjuvant chemotherapy
por: Montagna, Emilia, et al.
Publicado: (2020)

Practical consensus recommendations for neo-adjuvant chemotherapy in triple negative breast cancer
por: Bhattacharyya, G. S., et al.
Publicado: (2018)

Genetic variations in triple-negative breast cancers undergoing neo-adjuvant chemotherapy
por: Mori, Miki, et al.
Publicado: (2019)

Accuracy of MRI for prediction of response to neo-adjuvant chemotherapy in triple negative breast cancer
por: Bansal, GJ, et al.
Publicado: (2015)

Accuracy of MRI for prediction of response to neo-adjuvant chemotherapy in triple negative breast cancer compared to other subtypes of breast cancer
por: Bansal, Gaurav J, et al.
Publicado: (2016)

[(18)F]FDG and [(18)F]FLT PET for the evaluation of response to neo-adjuvant chemotherapy in a model of triple negative breast cancer
por: Raccagni, Isabella, et al.
Publicado: (2018)

Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)
por: Lluch, Ana, et al.
Publicado: (2020)

Overexpression of epithelial growth factor receptor (EGFR) predicts better response to neo-adjuvant chemotherapy in patients with triple-negative breast cancer
por: Tang, Yiqing, et al.
Publicado: (2012)

CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer
por: Slagter, Astrid E., et al.
Publicado: (2018)

Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study
por: Constantinidou, Anastasia, et al.
Publicado: (2020)

Residual Tumor Patterns of Breast Cancer on MRI after Neo-Adjuvant Chemotherapy: Impact on Clinicopathologic Factors and Prognosis
por: Cha, Yoon Jin, et al.
Publicado: (2022)

Successful treatment of gallbladder mixed adenoneuroendocrine carcinoma with neo-adjuvant chemotherapy
por: Song, Wu, et al.
Publicado: (2012)

Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy
por: Findlay, John M., et al.
Publicado: (2016)

Ki67 expression and the effect of neo-adjuvant chemotherapy on luminal HER2-negative breast cancer
por: Horimoto, Yoshiya, et al.
Publicado: (2014)

The Assessment of Response to Adjuvant Chemotherapy with CMF in Triple Negative Breast Cancer
por: Mousavi, Seyyed AsadoLah, et al.
Publicado: (2013)

Efficacy of Sequential Capecitabine on Adjuvant Chemotherapy of Triple-Negative Breast Cancer
por: Xi, Xun, et al.
Publicado: (2022)

Effectiveness of adjuvant chemotherapy for elderly patients with triple-negative breast cancer
por: Guo, Qiusheng, et al.
Publicado: (2023)

Pegylated Liposomal Doxorubicin (Caelyx(®)) as Adjuvant Treatment in Early-Stage Luminal B-like Breast Cancer: A Feasibility Phase II Trial
por: Dellapasqua, Silvia, et al.
Publicado: (2021)

Evaluation of Neo-Adjuvant, Concurrent and Adjuvant Chemotherapy in the Treatment of Head and Neck Squamous Cell Carcinoma: A Meta-Analysis
por: Akhlaghi, Fahimeh, et al.
Publicado: (2014)

Phase II study of neo-adjuvant chemotherapy for locally advanced gastric cancer
por: Chang, Alex Yuang-Chi, et al.
Publicado: (2016)

Neo-adjuvant chemotherapy in stage IIIC potentially resectable epithelial ovarian cancer
por: Voutsadakis, Ioannis A.
Publicado: (2016)

Impact of oncoplasty in increasing breast conservation rates Post neo-adjuvant chemotherapy
por: Koppiker, Chaitanyanand B., et al.
Publicado: (2023)

Changes in leukoencephalopathy and serum neurofilament after (neo)adjuvant chemotherapy for breast cancer
por: Schroyen, Gwen, et al.
Publicado: (2023)

Colorectal Cancer in the Elderly Patient: The Role of Neo-adjuvant Therapy
por: Dodaro, Concetta Anna, et al.
Publicado: (2019)

NEO adjuvant chemotherapy in breast cancer: What have we learned so far?
por: Raut, Nirmal V, et al.
Publicado: (2010)

Toxicity of (neo)adjuvant chemotherapy for BRCA1- and BRCA2-associated breast cancer
por: Drooger, Jan C., et al.
Publicado: (2016)

Chemotherapy and target therapy as neo-adjuvant approach for initially unresectable colorectal liver metastases
por: Rossi, Luigi, et al.
Publicado: (2012)

Neo Adjuvant Chemotherapy on Testicular Cancer after Scrotal Exploration: A Case Report
por: Novianda, Andhika H., et al.
Publicado: (2019)

NEPA efficacy and tolerability during (neo)adjuvant breast cancer chemotherapy with cyclophosphamide and doxorubicin
por: Yeo, Winnie, et al.
Publicado: (2022)

Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS)
por: Dikken, Johan L, et al.
Publicado: (2011)

Prediction of adjuvant chemotherapy response in triple negative breast cancer with discovery and targeted proteomics
por: Gámez-Pozo, Angelo, et al.
Publicado: (2017)

Negative Relationship between Post-Treatment Stromal Tumor-Infiltrating Lymphocyte (TIL) and Survival in Triple-Negative Breast Cancer Patients Treated with Dose-Dense Dose-Intense NeoAdjuvant Chemotherapy
por: Giacchetti, Sylvie, et al.
Publicado: (2022)

Adjuvant chemotherapy in locally advanced rectal cancer after neo-adjuvant concurrent chemoradiotherapy and surgery: A retrospective study in Vietnamese patients
por: Tran, Thang, et al.
Publicado: (2023)

A Single Institution Experience of Incorporation of Cisplatin into Adjuvant Chemotherapy for Patients With Triple-Negative Breast Cancer of Unknown BRCA Mutation Status
por: Su, Ying-Wen, et al.
Publicado: (2018)

Dermatomyositis as presenting feature of ovarian cancer, treated with neo-adjuvant chemotherapy and interval debulking surgery()
por: Christie, Alan, et al.
Publicado: (2013)

An immune surveillance model to monitor the response to neo-adjuvant chemotherapy treatment in breast cancer patients
por: Bernal-Estévez, David A, et al.
Publicado: (2015)

Neo-Adjuvant Chemotherapy Reduces, and Surgery Increases Immunosuppression in First-Line Treatment for Ovarian Cancer
por: De Bruyn, Christine, et al.
Publicado: (2021)

Isolated Leptomeningeal Metastasis of Breast Cancer During Neo-Adjuvant Chemotherapy: A Case Report
por: Uddin, Aaliya, et al.
Publicado: (2022)

Low-dose immunotherapy as a potentiator to increase the response with neo-adjuvant chemotherapy in oral cancers
por: Rathinasamy, Narmadha, et al.
Publicado: (2023)

Triple-Negative Breast Cancer: Adjuvant Therapeutic Options
por: Gucalp, Ayca, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_29na8d9e4vcn2n3cfh113gjtp5